Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06211413 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

Study acronym: SENTINEL
StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Aug 2026 → Jun 2027
See other at-risk trials from Abramson Cancer Center at Penn Medicine

Record History

  1. Primary and study completion pushed from Aug 2026 to Jun 2027 Secondary endpoints: details revised at 2 of 3 entries · Eligibility criteria expanded, about 5 words Show 2 more changesShow less
    • Secondary endpoints: details revised at 2 of 3 entries
    • Eligibility criteria expanded, about 5 words
  2. Study Identification, Study Status, Oversightv5
  3. Primary and study completion dates: Aug 2025 to Aug 2026v4
  4. Trial status: Not Yet Recruiting to Enrolling by Invitation Study sites: 0 to 1 · Start date changed from estimate of Jan 2024 to Feb 7, 2024v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2024 to Feb 7, 2024
  5. Secondary endpoints revised (3) Study description revised · Study title shortened, about 6 wordsv2 Show 2 more changesShow less
    • Study description revised
    • Study title shortened, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Abramson Cancer Center at Penn Medicine
170 trials monitored
See 20 trials at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Hypertension
1,795 trials monitored
See 85 trials at risk
Atrial Fibrillation
1,133 trials monitored
See 47 trials at risk
and 1 more disease
Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms. SENTINEL is an observational study that will use wearable technology to monitor heart rhythm and blood pressures at home to better understand how frequently patients are experiencing high blood pressure and/or abnormal heart rhythms.
Trial Details
NCT Number NCT06211413
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov